Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lumos Pharma (LUMO)
NASDAQ:LUMO
Holding LUMO?
Track your performance easily
LUMO Stock Chart & Stats
Day’s Range$4.33 - $4.39
52-Week Range― - ―
Previous Close$4.34
Volume481.69K
Average Volume (3M)N/A
Market Cap
$37.54M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding8,648,618
10 Day Avg. Volume144,758
30 Day Avg. Volume113,626
Standard Deviation0.31
R-Squared0.02
Alpha0.00732
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)7.61
Price to Sales (P/S)17.02
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.13Price Target Upside133.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Lumos Pharma News
PremiumCompany Announcements
Lumos Pharma Completes Merger and Delisting Process
PremiumCompany Announcements
Lumos Pharma Faces Uncertainty as CVRs Risk Expiring Worthless Post-Merger
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe company met all primary and secondary endpoints in its Phase 2 OraGrowtH210 and OraGrowtH212 studies of LUM-201 in PGHD.
FDA ApprovalThe FDA is aligned with Lumos Pharma on the final Phase 3 trial design for LUM-201 in pediatric growth hormone deficiency patients.
Merger AgreementLumos Pharma announced a definitive merger agreement with Double Point Ventures, with Lumos' outstanding shares to be acquired at $4.25 per share in cash.
Bears Say
Cash Flow ConcernsLumos Pharma's cash runway is limited to the fourth quarter of 2024, restricting better alternatives for the company.
Financial PerformanceThe announced merger has led to a downgrade of Lumos Pharma stock to a Neutral rating from Buy.
Merger ValuationThe valuation of the merger with Double Point Ventures is considered disappointing, with a modest premium to the stock's recent price.
---
Ownership Overview
― Insiders
0.85% Mutual Funds
0.79% Other Institutional Investors
97.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LUMO FAQ
What was Lumos Pharma’s price range in the past 12 months?
Currently, no data Available
What is Lumos Pharma’s market cap?
Currently, no data Available
When is Lumos Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lumos Pharma’s earnings last quarter?
Currently, no data Available
Is Lumos Pharma overvalued?
According to Wall Street analysts Lumos Pharma’s price is currently Undervalued.
Does Lumos Pharma pay dividends?
Lumos Pharma does not currently pay dividends.
What is Lumos Pharma’s EPS estimate?
Lumos Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lumos Pharma have?
Currently, no data Available
What happened to Lumos Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lumos Pharma?
Among the largest hedge funds holding Lumos Pharma’s share is Blackstone Inc.. It holds Lumos Pharma’s shares valued at N/A.
---
Lumos Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.13 (133.41% Upside)
$10.13 (133.41% Upside)
Hedge Fund Trend
Decreased
By 78.6K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.28%
12-Months-Change
Fundamentals
Return on Equity
-172.83%
Trailing 12-Months
Asset Growth
-63.43%
Trailing 12-Months
Company Description
Lumos Pharma
NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.
---
LUMO Stock 12 Month Forecast
Average Price Target
$10.13
▲(133.41% Upside)
Technical Analysis
Best Analysts Covering LUMO
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+13.24%
reiterated a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +13.24% per trade.
---